Cargando…

Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era

Background: Extra-intestinal manifestations are frequent in inflammatory bowel disease (IBD). Ocular disorders are generally under diagnosed as they are challenging diagnosis. Aims: We assessed the prevalence of ophthalmological manifestations in patients with IBD, and investigated characteristics a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuny, Alix, Guillo, Lucas, Baumann, Cédric, Netter, Patrick, Danese, Silvio, Caron, Bénédicte, Peyrin-Biroulet, Laurent, Angioi, Karine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369806/ https://www.ncbi.nlm.nih.gov/pubmed/35956153 http://dx.doi.org/10.3390/jcm11154538

Ejemplares similares

Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic
por: Bonsack, Olivier, et al.
Publicado: (2023)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
por: Wils, Pauline, et al.
Publicado: (2022)

Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
por: Danese, Silvio, et al.
Publicado: (2021)

Impact of the Exposome on the Epigenome in Inflammatory Bowel Disease Patients and Animal Models
por: Vieujean, Sophie, et al.
Publicado: (2022)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Can we change the natural course of inflammatory bowel disease?
por: Le Berre, Catherine, et al.
Publicado: (2023)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
por: Furfaro, Federica, et al.
Publicado: (2022)

Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
por: Kotze, Paulo Gustavo, et al.
Publicado: (2021)

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey
por: Caron, Bénédicte, et al.
Publicado: (2021)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Risk-Benefit of IBD Drugs: A Physicians and Patients Survey
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease
por: Honap, Sailish, et al.
Publicado: (2023)

PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
por: Spadaccini, Marco, et al.
Publicado: (2017)

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
por: Wils, Pauline, et al.
Publicado: (2023)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Ultrasound Elastography in Inflammatory Bowel Diseases: A Systematic Review of Accuracy Compared with Histopathological Assessment
por: Dal Buono, Arianna, et al.
Publicado: (2022)

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
por: Magalhaes, Diogo, et al.
Publicado: (2023)

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey
por: D'Amico, Ferdinando, et al.
Publicado: (2020)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Protecting patients with IBD during the COVID-19 pandemic
por: Fiorino, Gionata, et al.
Publicado: (2020)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Viral infections in inflammatory bowel disease: Tips and tricks for correct management
por: Craviotto, Vincenzo, et al.
Publicado: (2021)

Efficacy, Safety, and Concerns on Microbiota Modulation, Antibiotics, Probiotics, and Fecal Microbial Transplant for Inflammatory Bowel Disease and Other Gastrointestinal Conditions: Results from an International Survey
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2023)

Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Bonovas, Stefanos, et al.
Publicado: (2016)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts
por: Allocca, Mariangela, et al.
Publicado: (2020)

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_85b331vhr8mkb32kl3sm4mvldr